Cardiff Oncology Inc
Cardiff Oncology Inc logo
CRDF

Cardiff Oncology Inc (CRDF)

$1.576.08%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.46
Day's Range
$1.57
$1.13
52-Week Range
$7.32
1 month return10.56%
3 month return38.43%
1 year return70.27%
5 year return96.07%

Company Information

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to overcome resistance, improve response to treatment and increase overall survival. The company is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff has three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021.
OrganizationCardiff Oncology Inc
Employees22
CEODr. Mark Erlander Ph.D.
IndustryHealth Services

Analyst Recommendation

based on 5 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 5 Wall street analysts offering stock ratings for Cardiff Oncology Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 409.55%

Current

$1.57

Target

$8.0

Recommendation Trend

Based on 5 analyst

Current1M Ago3M Ago
Buy
5
10
9
Hold
0
1
1
Sell
0
0
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
66.1M
Book Value
$2.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.84
Wall Street Target Price
8.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.55
Enterprise Value
-49353736
Enterprise Value/Revenue
15.04
Enterprise Value/Ebitda
1.26

Technicals

Beta
1.52
50 Day MA
1.48
200 Day MA
2.01

Institutional Holdings

Vanguard Group Inc

4.35%

Artal Group S A

1.68%

Renaissance Technologies Corp

1.63%

LAURION CAPITAL MANAGEMENT LP

1.62%

Geode Capital Management, LLC

0.92%

Millennium Management LLC

0.88%

Discover more

Frequently Asked Questions

What is Cardiff Oncology Inc share price today?

Can Indians buy Cardiff Oncology Inc shares?

How can I buy Cardiff Oncology Inc shares from India?

Can Fractional shares of Cardiff Oncology Inc be purchased?

What are the documents required to start investing in Cardiff Oncology Inc stocks?

What are today’s High and Low prices of Cardiff Oncology Inc?

What are today’s traded volumes of Cardiff Oncology Inc?

What is today’s market capitalisation of Cardiff Oncology Inc?

What is the 52 Week High and Low Range of Cardiff Oncology Inc?

How much percentage Cardiff Oncology Inc is down from its 52 Week High?

How much percentage Cardiff Oncology Inc is up from its 52 Week low?

What are the historical returns of Cardiff Oncology Inc?

Who is the Chief Executive Officer (CEO) of Cardiff Oncology Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*